Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma

Expert Rev Respir Med. 2016;10(5):481-90. doi: 10.1586/17476348.2016.1161508. Epub 2016 Mar 16.


Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the correct choice of device and proper inhalation technique, this influences drug delivery and distribution along the bronchial tree, including the most peripheral airways. The fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) is the only extrafine formulation available in pressurized metered dose inhaler (pMDI) and in dry powder inhaler (DPI). Here, we focus on the recent significant advances regarding BDP/FF fixed combination for the treatment of asthma.

Keywords: Asthma; DPI; beclometasone dipropionate/formoterol fumarate; extrafine; fixed combination; inflammation; pMDI; small airways.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Inhalation
  • Anti-Asthmatic Agents / administration & dosage
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Beclomethasone / administration & dosage
  • Beclomethasone / therapeutic use*
  • Drug Combinations
  • Dry Powder Inhalers
  • Formoterol Fumarate / administration & dosage
  • Formoterol Fumarate / therapeutic use*
  • Humans
  • Metered Dose Inhalers
  • Treatment Outcome


  • Anti-Asthmatic Agents
  • Drug Combinations
  • Beclomethasone
  • Formoterol Fumarate